Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
TOVX is expected to report earnings to fall 14.29% to -5 cents per share on March 18
Q4'26
Est.
$-0.06
Q2'26
Missed
by $0.01
Q1'26
Beat
by $0.16
Q4'25
Beat
by $1.17
Q3'25
Beat
by $0.68
The last earnings report on August 11 showed earnings per share of -7 cents, missing the estimate of -5 cents. With 270.67K shares outstanding, the current market capitalization sits at 9.02M.